Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Rottapharm Biotech
2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?
Despite Indian companies not being able to honor COVID-19 vaccine export commitments, Biological E’s MD believes mitigating circumstances mean relations with the agency won’t be damaged. Meanwhile, Corbevax is being used in India's immunization program and a tech transfer for Johnson & Johnson’s COVID-19 vaccine is going ahead.
Keep your eyes on Asia, both for groundbreaking innovation and huge market opportunities, says Alex Gorsky, executive chairman of Johnson & Johnson. He also outlines exciting possibilities as biology and chemistry are being “fundamentally digitized.”
If study finds biosimilar uptake in the Part B program is lagging, it may inform policy changes to encourage gains. On the other hand, the latest biosimilars trend reports from Cardinal Health and Amgen show follow-ons are controlling share in some markets for physician-administered drugs and savings are adding up.
- OTC, Consumer
- Other Names / Subsidiaries
- Madaus Pharma
- Rottapharm Madaus